Biotech: Page 95
-
Biogen makes a billion-dollar bet on Parkinson's drugs
In one of its biggest deals to date, Biogen plans to take an equity stake in Denali Therapeutics to gain access to new treatments for Parkinson's disease.
By Jacob Bell • Aug. 6, 2020 -
Moderna sets high price in early coronavirus vaccine supply deals
Early preorders for small quantities of Moderna's shot set a price per dose of $32 to $37, although the biotech plans to charge less in larger agreements.
By Ned Pagliarulo • Aug. 5, 2020 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Courtesy of Novavax, Australian Broadcasting Corporation
With first results, Novavax takes step forward in coronavirus vaccine race
Early-stage results appear to show that Novavax's shot passed its first meaningful test, helping the Maryland biotech keep pace with larger competitors.
By Ben Fidler • Aug. 4, 2020 -
FDA rejects a peanut allergy treatment, sinking a small biotech's shares
Given the long list of requirements in the FDA's rejection letter, DBV Technologies likely has years of work ahead to win approval of Viaskin Peanut.
By Jacob Bell • Aug. 4, 2020 -
Amarin decides to go it alone in Europe, as uncertainty clouds heart drug's US future
Chief executive John Thero said the company decided against "multiple proposals" for sales partnerships on Vascepa in Europe. Doing so, however, keeps the pressure on Amarin to deliver.
By Ben Fidler • Aug. 4, 2020 -
Pfizer spinoff Cerevel to raise $445M in merger with blank-check company
Deals involving so-called special purpose acquisition companies, or SPACs, have boomed, offering the neuroscience-focused Cerevel an unorthodox, and lucrative, path to go public.
By Ned Pagliarulo • July 30, 2020 -
Jonathan Gardner/BioPharma Dive
Gilead's second act in cell therapy gets its first approval
The FDA approval of Tecartus, for mantle cell lymphoma, means two products have now emerged from Gilead's 2017 buyout of Kite Pharma.
By Jacob Bell • July 24, 2020 -
Moderna, pacing a global vaccine race, loses a key patent fight
A patent board ruled that Arbutus Biopharma invented a technology Moderna uses to deliver its vaccines, which may have implications for its industry-leading coronavirus shot.
By Jonathan Gardner • July 24, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
On eve of first big coronavirus vaccine study, trial leaders brace for 'unprecedented' task
Researchers will need millions of volunteers to find the roughly 150,000 required for the five Phase 3 trials expected this year. Here's what lies ahead for them.
By Ben Fidler • July 24, 2020 -
Permission granted by BioNTech SE
Coronavirus vaccines speed ahead, but experts fear not everyone will take them
Gaining trust will be a tough task as public health officials gear up for one of the biggest immunization campaigns in decades.
By Jonathan Gardner • July 23, 2020 -
Biogen points to COVID-19 for disappointing drug launch
Sales of Vumerity, a key new product in Biogen's plan to bolster its multiple sclerosis drug business, have been slow since it launched in December.
By Jacob Bell • July 22, 2020 -
At a pivotal moment, Biogen loses another top executive
Just weeks after Biogen submitted its closely watched Alzheimer's drug to the FDA, the company announced its CFO Jeff Capello will depart next month.
By Jacob Bell • July 22, 2020 -
Permission granted by Gilead Sciences
Gilead adds to string of cancer drug deals with Tizona stake
An upfront payment of $300 million gives Gilead a nearly 50% stake in Tizona Therapeutics and the exclusive option to acquire it later, depending on how promising the biotech's immunotherapy looks.
By Jacob Bell • July 21, 2020 -
Permission granted by University of Maryland School of Medicine
Pfizer and BioNTech coronavirus vaccine gets boost from German data
As the race to bring a vaccine to market accelerates, the companies unveiled new clinical results and a deal that promises the U.K. 30 million doses of a successful shot.
By Jonathan Gardner • July 20, 2020 -
Getty Images
Sponsored by Parexel BiotechOpportunities for biotechs in precision medicine
Exploring the promise of precision medicine in helping biotechs bring new therapies to patients.
By Angela Qu, MD, PhD, Vice President, and Arlene Hughes, PhD, Senior Director • July 20, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
A startup launches with big plans to develop antibody drugs for coronaviruses
Larger drugmakers like Regeneron have led the way in developing antibody drugs for COVID-19. Adagio Therapeutics aims to prove it can follow suit, with an eye to future coronavirus outbreaks as well.
By Ben Fidler • July 16, 2020 -
Researchers publish long-awaited study data on Moderna coronavirus vaccine
The results support the biotech's earlier claim of positive results, but don't show whether the vaccine protects against infection. Still, "we're so hungry for a vaccine we're trying to read the tea leaves," said vaccine expert Paul Offit.
By Ned Pagliarulo • Updated July 14, 2020 -
Preventive studies for Eisai, Biogen Alzheimer's drug could add years to amyloid debate
Two late-stage trials will assess the companies' experimental drug BAN2401 in people without Alzheimer's symptoms but with biological signs of the disease.
By Jonathan Gardner • July 14, 2020 -
Permission granted by Roche
Blueprint, eyeing an independent future, gets $775M in new Roche alliance
The deal, which gives Roche rights to Blueprint's lead drug pralsetinib, is another bet by the Swiss drugmaker on targeted cancer therapies.
By Ben Fidler • Updated July 14, 2020 -
Jonathan Gardner/BioPharma Dive
Beigene, already flush with cash, raising $2B from investors
Amgen, which last year partnered with the Chinese biotech, will invest another $420 million in the company to maintain its roughly 20% stake.
By Ned Pagliarulo • July 13, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
India clears a psoriasis drug for COVID-19, and a tiny US biotech's shares soar
An emergency approval for Biocon's drug Alzumab in India could lead its U.S. partner, Equillium, to start broader trials in coronavirus disease.
By Ben Fidler • July 13, 2020 -
Big pharma, battling COVID-19, looks to 'buy time' on another health crisis: superbugs
Facing an alarming scarcity of new antibiotics, about two dozen of the world's largest drugmakers are backing a fund meant to develop two to four by 2030.
By Jacob Bell • July 9, 2020 -
ALS drug development
In the hunt for ALS treatments, researchers find promise in silencing genes
Two studies published in the New England Journal of Medicine, including one that tested a Biogen drug, provide some evidence that a decades-long effort to develop genetic medicines for ALS is starting to pay off.
By Jacob Bell • July 8, 2020 -
Biogen submitted its Alzheimer's drug for approval. Now what?
The later-than-expected filing is just the first of many hurdles Biogen faces in trying to get aducanumab approved. Some analysts on Wall Street don't have high hopes for the drug's chances.
By Jacob Bell • July 8, 2020 -
US buys up early supply of Regeneron's COVID-19 antibody cocktail
A $450 million grant will help Regeneron scale up manufacturing of its drug, which is among the front-running antibody therapies for COVID-19.
By Jonathan Gardner • July 7, 2020
Previous
